RecruitingPhase 1NCT05225363

Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer

A Phase 1 Study to Evaluate TAG72-Targeting Chimeric Antigen Receptor (CAR) T Cells in Patients With Advanced Epithelial Ovarian Cancer

Sponsor

City of Hope Medical Center

Enrollment

33 participants

Start Date

May 5, 2022

Study Type

INTERVENTIONAL

Conditions

Platinum-Resistant Ovarian Carcinoma

Summary

This phase I trial tests the safety, side effects, and best dose of TAG72-chimeric antigen receptor (CAR) T cells in treating patients with epithelial ovarian cancer that remains despite treatment with platinum therapy (platinum resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and will have a new gene put in them that makes them able to recognize TAG72, a protein on the surface of tumor cells. These TAG72-specific T cells may help the body's immune system identify and kill TAG72+ cancer cells.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a new type of cell therapy called TAG72-CAR T cells — immune cells that have been genetically modified to seek out and attack ovarian cancer cells — in women whose ovarian cancer has stopped responding to platinum-based chemotherapy. **You may be eligible if...** - You are 18 or older - You have been diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Your cancer is resistant to platinum-based chemotherapy - Your tumor expresses a protein called TAG72 (confirmed by testing) - You are well enough to participate (good performance status) and have adequate organ function **You may NOT be eligible if...** - Your tumor does not express the TAG72 protein - You have active autoimmune disease requiring immunosuppressive treatment - You have untreated brain metastases - You have severe organ dysfunction (heart, liver, kidney) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.